Franklin Biotechnology Discovery Fund Class A (FBDIX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
115.14
+0.14 (0.12%)
Jun 18, 2025, 4:00 PM EDT
-15.64% (1Y)
Fund Assets | 804.12M |
Expense Ratio | 1.05% |
Min. Investment | $1,000 |
Turnover | n/a |
Dividend (ttm) | 11.76 |
Dividend Yield | 9.65% |
Dividend Growth | n/a |
Payout Frequency | n/a |
Ex-Dividend Date | Dec 20, 2024 |
Previous Close | 115.00 |
YTD Return | -4.38% |
1-Year Return | -0.50% |
5-Year Return | -6.48% |
52-Week Low | 99.30 |
52-Week High | 152.68 |
Beta (5Y) | 0.56 |
Holdings | 88 |
Inception Date | Sep 15, 1997 |
About FBDIX
The Franklin Biotechnology Discovery Fund Class A (FBDIX) seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms.
Fund Family FrankTemp/Franklin A
Category Health
Stock Exchange NASDAQ
Ticker Symbol FBDIX
Share Class Class A
Index NASDAQ Biotechnology CR
Performance
FBDIX had a total return of -0.50% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.31%.
Top 10 Holdings
49.47% of assetsName | Symbol | Weight |
---|---|---|
Gilead Sciences, Inc. | GILD | 8.17% |
Amgen Inc. | AMGN | 7.64% |
Vertex Pharmaceuticals Incorporated | VRTX | 7.25% |
Ascendis Pharma A/S | ASND | 4.89% |
Regeneron Pharmaceuticals, Inc. | REGN | 4.34% |
argenx SE | ARGX | 3.80% |
Jazz Pharmaceuticals plc | JAZZ | 3.79% |
Merus N.V. | MRUS | 3.52% |
PTC Therapeutics, Inc. | PTCT | 3.16% |
Neurocrine Biosciences, Inc. | NBIX | 2.91% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 20, 2024 | $11.7607 | Dec 20, 2024 |
Dec 20, 2022 | $0.1411 | Dec 20, 2022 |
Dec 15, 2021 | $17.6831 | Dec 15, 2021 |
Dec 15, 2020 | $10.3921 | Dec 15, 2020 |
Dec 16, 2019 | $14.1643 | Dec 18, 2019 |
Dec 17, 2018 | $4.5496 | Dec 19, 2018 |